Zepbound, Mounjaro Drove Growth in Q4 2024 for Eli Lilly
In 2024, the US Food and Drug Administration (FDA) approved Eli Lilly’s Zepbound for a new indication as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The injectable Zepbound originally launched in the United States for the treatment of adult patients with obesity or overweight with weight-related…